By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


Start Up


Dyax  Antibody phage display

Company News
Merrimack (MACK) Release: Final Results Of NAPOLI-1 Study Confirm Overall Survival And Progression-Free Survival Benefit For The ONIVYDE Regimen For Patients With Metastatic Pancreatic Cancer 10/11/2016 6:57:29 AM
Merrimack (MACK) CEO Steps Down as Company Slashes 22% of Jobs 10/3/2016 5:52:12 AM
Merrimack (MACK) To Present Final Results Of Phase 3 NAPOLI-1 Study At The European Society For Medical Oncology 2016 Congress 9/29/2016 10:52:11 AM
Merrimack (MACK) Reports Second Quarter 2016 Financial Results 8/5/2016 7:58:27 AM
Merrimack (MACK) Announces ONIVYDE Regimen Receives Positive CHMP Opinion In European Union 7/25/2016 6:37:09 AM
Merrimack (MACK) Announces Timing Of Second Quarter 2016 Investor Conference Call 7/20/2016 8:00:12 AM
FDA Grants Merrimack (MACK) Fast Track Designation For Seribantumab (MM-121) In Non-Small Cell Lung Cancer 7/6/2016 6:34:23 AM
Merrimack (MACK) Release: NAPOLI-1 Data Demonstrates ONIVYDE Regimen Maintains Quality Of Life While Improving Overall Survival In Patients With Metastatic Pancreatic Cancer 6/30/2016 8:28:51 AM
Merrimack (MACK) To Present New Analyses Of Phase 3 NAPOLI-1 Data At The ESMO 18th World Congress On Gastrointestinal Cancer 6/22/2016 6:05:21 AM
ASCO2016: Merrimack (MACK) Release: Final Analysis Of First-In-Human Phase 1 Study Of MM-151 Shows Positive Clinical Activity In Multiple Solid Tumor Types, Including Colorectal Cancer 6/6/2016 9:17:09 AM